Clinical trial · Observational
Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
A Prospective Study of Circulating Tumor DNA Detection in Surveillance for Stage ⅢA Non-small-cell Lung Cancer Patients
NCT02696525CI-TRIAL-00033031unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Conduct a prospective study to confirm blood and urine ctDNA detection value in non-small-cell lung cancer patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Non-small-cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Lead time of tumor relapse detection by blood or urine circulation tumor DNA than radiographic approaches
- timeFrame
- 4 years
Secondary outcomes (5)
- measure
- Lead time of tumor relapse detection by blood or urine circulation tumor DNA than tumor markers
- timeFrame
- 4 years
- measure
- The concordance of ctDNA genomic alterations detection in peripheral blood and urine with those in matched tumor sample
- timeFrame
- 1 year
- measure
- Correlation of blood and urine ctDNA concentration before surgery with clinical features and prognosis
- timeFrame
- 4 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 to 80 years * Undergo radical surgery（R0 resection） * Histologically confirmed diagnosis of stage ⅢA non-small cell lung cancer * Positive Driver mutation(EGFR、PTEN、PIK3CA、BRAF、K-RAS、Her2) in tumor tissue * Blood or urine circulating tumor detect the driver mutation detected in tumor tissue * Patients must have given written informed consent Exclusion Criteria: * Unable to comply with the study procedure * Malignant tumor history within the past 5 years * Patients who received any treatment prior to resection * R1 or R2 resection * Coexisting small cell lung cancer * Received target drug therapy after surgery * Unqualified blood or urine samples
References
Publications (0)
Data not yet available
No reference posted for this study.